Immunosuppressive therapy of autoimmune diseases
JF Bach - Trends in Pharmacological Sciences, 1993 - cell.com
JF Bach
Trends in Pharmacological Sciences, 1993•cell.comCiclosporin and cyclophosphamide show a remarkable efficacy in most autoimmune
diseases. However, their effect is dependent on continuous drug administration with risks of
drug toxicity and over immunosuppression. Results recently obtained in animal models,
discussed here by Jean Francois Bach particularly with anti-CD3 and anti-CD4 monoclonal
antibodies, indicate that reestablishmenf of tolerance to self antigens is a feasible goal.
Autoimmune diseases are diverse and may involve most organs to various degrees …
diseases. However, their effect is dependent on continuous drug administration with risks of
drug toxicity and over immunosuppression. Results recently obtained in animal models,
discussed here by Jean Francois Bach particularly with anti-CD3 and anti-CD4 monoclonal
antibodies, indicate that reestablishmenf of tolerance to self antigens is a feasible goal.
Autoimmune diseases are diverse and may involve most organs to various degrees …
Ciclosporin and cyclophosphamide show a remarkable efficacy in most autoimmune diseases. However, their effect is dependent on continuous drug administration with risks of drug toxicity and over immunosuppression. Results recently obtained in animal models, discussed here by Jean Francois Bach particularly with anti-CD3 and anti-CD4 monoclonal antibodies, indicate that reestablishmenf of tolerance to self antigens is a feasible goal.
Autoimmune diseases are diverse and may involve most organs to various degrees. Although these diseases are of an immune nature their treatment has been, and often remains, essentially symptomatic (for example, substitutive hormones in autoimmune diseases of the endocrine glands and anti-inflammatory drugs in rheumatoid arthritis). Immunosuppressive treatment has been attempted in some autoimmune diseases. However, until 1980, success had usually been limited and the risk of side-effects was a major concern in diseases that are not usually life threatening. The discovery of new immunosuppressive drugs, especially ciclosporin, and the emergence of immunologically active biological products (monoclonal antibodies, cytokines and peptides) has dramatically changed the approach to the problem by showing that a number of dis-
cell.com